MediWound (NASDAQ:MDWD – Get Free Report) and Ocugen (NASDAQ:OCGN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.
Insider and Institutional Ownership
46.8% of MediWound shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for MediWound and Ocugen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 1 | 2 | 0 | 2.25 |
| Ocugen | 1 | 0 | 4 | 0 | 2.60 |
Profitability
This table compares MediWound and Ocugen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -170.10% | -47.24% | -24.27% |
| Ocugen | N/A | -127,987.80% | -115.95% |
Earnings & Valuation
This table compares MediWound and Ocugen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $16.96 million | 10.18 | -$23.88 million | ($1.80) | -7.47 |
| Ocugen | $4.58 million | 98.45 | -$67.85 million | ($0.26) | -5.12 |
MediWound has higher revenue and earnings than Ocugen. MediWound is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
MediWound has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500.
Summary
Ocugen beats MediWound on 8 of the 14 factors compared between the two stocks.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
About Ocugen
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
